Join Your Exclusive TIL Community to Capitalize on the
Ultimate Personalized Immunotherapy Approach for Solid Tumors
TIL therapies are returning to the forefront of solid tumor treatment to take advantage of their inherent ability to target heterogeneous antigens and survive in the hostile tumor microenvironment. Now with advances in TIL selection through the benchmarking of optimal biomarkers, streamlined manufacturing processes to improve turnaround time and cost of goods, and commercialization discussions on the horizon… it is time to get caught up to speed on the fast-evolving TIL approach.
Join the TIL Therapies Summit; the only industry-focused event dedicated to TIL therapies this October to network and learn from the pioneers of Iovance, Turnstone Biologics, MD Anderson, Achilles Therapeutics and Obsidian Therapeutics.
Promising comprehensive content critical to your clinical and commercial development including:
- QC and potency assay development to bridge clinical data and remove variability
- Biomarker and target identification to improve T cell selection
- Cutting-edge genetic engineering approaches to enhance TIL function
Don’t miss out on the chance to collaborate with the leaders of TIL treatment, improve your competitive intelligence and capitalize on the cell therapy approach which holds the most promise for solid tumors.